RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
205 hedge funds and large institutions have $2.58B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
22% more funds holding
Funds holding: 168 → 205 (+37)
28% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 65
Holders
205
Holding in Top 10
9
Calls
$222M
Puts
$110M
Top Buyers
| 1 | +$197M | |
| 2 | +$66.3M | |
| 3 | +$33.1M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$31.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$28.5M |
Top Sellers
| 1 | -$121M | |
| 2 | -$76M | |
| 3 | -$49.9M | |
| 4 |
Morgan Stanley
New York
|
-$44.6M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$43.2M |